Towards biomarker-based diagnosis of Parkinson disease
Towards biomarker-based diagnosis of Parkinson disease
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Barcelona, ES · Author affiliation
Parkinson's Disease & Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. eduardtolosa@gmail.com.Location evidence
Centro, ES · Author affiliation
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Barcelona, Spain. eduardtolosa@gmail.com.Location evidence
Innsbruck, AT · Author affiliation
Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.Location evidence
London, GB · Author affiliation
Centre for Preventive Neurology, Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.Location evidence
Stockholm, SE · Author affiliation
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.Location evidence
Follow the study behind this paper
App-supported activity for people with a dream-sleep movement disorder
The registry links this paper to the study.
A plain-language reading has not been prepared for this paper yet.
Original abstract
The current clinical diagnostic criteria for Parkinson disease (PD) have limitations and are inherently insensitive to the earliest stages of disease, when classical motor signs can be absent. Imaging and genetic tests are currently used to support or establish a diagnosis of PD, but no validated biomarker-based diagnostic framework currently exists. Substantial progress has been made in the field of molecular disease markers, most notably with the development and validation of seed amplification assays (SAAs), which enable detection of very low levels of pathological α-synuclein in the cerebrospinal fluid and other biofluids and tissue. In this Review, we discuss the potential of α-synuclein SAAs and other biomarkers to improve diagnostic accuracy and enable earlier diagnosis of PD. We consider biological disease definitions that have been proposed on the basis of these biomarkers, highlighting their merits, limitations and implications for PD research and clinical management. Research is ongoing to determine the predictive value of PD biomarkers in healthy people and people with prodromal PD and to develop markers that are sensitive to disease progression, both of which are key for implementation of trials involving drugs designed to modify or prevent disease. Integrating clinical, genetic, molecular and imaging biomarkers should enable earlier, more accurate diagnosis of PD and characterization of PD subtypes, thereby enabling personalized treatment to slow or even prevent PD.